SRR1413414
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1453214 | GTEX | — | 0.980 |
| 2 | SRR1459033 | GTEX | — | 0.977 |
| 3 | SRR1322291 | GTEX | — | 0.976 |
| 4 | SRR1434867 | GTEX | — | 0.974 |
| 5 | SRR1456514 | GTEX | — | 0.973 |
| 6 | SRR1404969 | GTEX | — | 0.972 |
| 7 | SRR1474754 | GTEX | — | 0.972 |
| 8 | SRR1377984 | GTEX | — | 0.971 |
| 9 | SRR1394936 | GTEX | — | 0.970 |
| 10 | SRR1348770 | GTEX | — | 0.969 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 4 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.218 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.054 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.003 | Idelalisib | — uncovered |